Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT
Regulatory Filings Classification · 90% confidence The document is a Rule 424(b)(3) Prospectus Supplement to a Form F-1 registration and a Form 6-K (foreign private issuer report) containing securities offering and executive appointment disclosures. It does not present full financial statements (10-K, IR) nor a press release, earnings release, or other specialized category. This is a regulatory filing of an offering document, so it falls under Regulatory Filings (RNS).
2026-06-02 English
PROSPECTUS SUPPLEMENT
Board/Management Information Classification · 93% confidence The document is a Form 6-K current report by a foreign private issuer that primarily announces the appointment of a new Chief Financial Officer and furnishes the related employment agreement and press release. This is an announcement of a senior management change, fitting the ‘Board/Management Information’ category rather than a full report or financial filing. Therefore, it should be classified as MANG.
2026-06-02 English
PROSPECTUS SUPPLEMENT
Board/Management Information Classification · 91% confidence The document is a Form 6-K furnishing a press release and details regarding the appointment of a new Chief Financial Officer and the related employment agreement. This clearly constitutes an announcement of a change in senior management. Under the provided definitions, this falls under Board/Management Information (Code: MANG).
2026-06-02 English
PROSPECTUS SUPPLEMENT
Board/Management Information Classification · 88% confidence The document is a Form 6-K report by a foreign private issuer that primarily announces the appointment of a new Chief Financial Officer (James Levine) and furnishes a related press release and employment agreement. This is a senior management change notice, fitting the “Board/Management Information” category rather than a full financial report or mere publication announcement.
2026-06-02 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 90% confidence The document is a Form 6-K filing by a foreign private issuer that announces the appointment of a new Chief Financial Officer, detailing the employment agreement and associated terms. This constitutes a senior management change announcement. Therefore, it fits the "Board/Management Information" category (Code: MANG).
2026-06-02 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2026-05-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.